Breast Cancer

Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, discusses a study analyzing radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the potential impact of the cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer.

Women with early sentinel lymph node-positive breast cancer achieve as much of a disease-free and survival benefit from axillary radiotherapy as they do from axillary lymph node dissection with significantly less risk of lymphedema.

Jane E. Churpek, MD, discusses a study that found the inherited mutations in breast cancer genes in African American breast cancer patients were revealed by targeted genomic capture and next-generation sequencing.

New research suggests that HER2-targeted drugs may actually have much broader applications, benefiting patients who are not designated HER2-positive by routine testing.

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.

Clifford A. Hudis, MD, ASCO President-Elect, describes the focus on global medicine at the 2013 American Society of Clinical Oncology Annual Meeting.

A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.

Max S. Wicha, MD, is an internationally renowned research expert in the field of breast oncology. His lab was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.